Cargando…

Direct improvement of quality of life using a tailored quality of life diagnosis and therapy pathway: randomised trial in 200 women with breast cancer

BACKGROUND: Despite thousands of papers, the value of quality of life (QoL) in curing disease remains uncertain. Until now, we lacked tools for the diagnosis and specific treatment of diseased QoL. We approached this problem stepwise by theory building, modelling, an exploratory trial and now a defi...

Descripción completa

Detalles Bibliográficos
Autores principales: Klinkhammer-Schalke, M, Koller, M, Steinger, B, Ehret, C, Ernst, B, Wyatt, J C, Hofstädter, F, Lorenz, W
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3305975/
https://www.ncbi.nlm.nih.gov/pubmed/22315052
http://dx.doi.org/10.1038/bjc.2012.4
_version_ 1782227168284114944
author Klinkhammer-Schalke, M
Koller, M
Steinger, B
Ehret, C
Ernst, B
Wyatt, J C
Hofstädter, F
Lorenz, W
author_facet Klinkhammer-Schalke, M
Koller, M
Steinger, B
Ehret, C
Ernst, B
Wyatt, J C
Hofstädter, F
Lorenz, W
author_sort Klinkhammer-Schalke, M
collection PubMed
description BACKGROUND: Despite thousands of papers, the value of quality of life (QoL) in curing disease remains uncertain. Until now, we lacked tools for the diagnosis and specific treatment of diseased QoL. We approached this problem stepwise by theory building, modelling, an exploratory trial and now a definitive randomised controlled trial (RCT) in breast cancer, whose results we report here. METHODS: In all, 200 representative Bavarian primary breast cancer patients were recruited by five hospitals and treated by 146 care professionals. Patients were randomised to either (1) a novel care pathway including diagnosis of ‘diseased’ QoL (any QoL measure below 50 points) using a QoL profile and expert report sent to the patient's coordinating practitioner, who arranged QoL therapy consisting of up to five standardised treatments for specific QoL defects or (2) standard postoperative care adhering to the German national guideline for breast cancer. The primary end point was the proportion of patients in each group with diseased QoL 6 months after surgery. Patients were blinded to their allocated group. RESULTS: At 0 and 3 months after surgery, diseased QoL was diagnosed in 70% of patients. The QoL pathway reduced rates of diseased QoL to 56% at 6 months, especially in emotion and coping, compared with 71% in controls (P=0.048). Relative risk reduction was 21% (95% confidence interval (CI): 0–37), absolute risk reduction 15% (95% CI: 0.3–29), number needed to treat (NNT)=7 (95% CI: 3–37). When QoL therapy finished after successful treatment, diseased QoL often returned again, indicating good responsiveness of the QoL pathway. CONCLUSION: A three-component outcome system including clinician-derived objective, patient-reported subjective end points and qualitative analysis of clinical relevance was developed in the last 10 years for cancer as a complex intervention. A separate QoL pathway was implemented for the diagnosis and treatment of diseased QoL and its effectiveness tested in a community-based, pragmatic, definitive RCT. While the pathway was active, it was effective with an NNT of 7.
format Online
Article
Text
id pubmed-3305975
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-33059752012-03-16 Direct improvement of quality of life using a tailored quality of life diagnosis and therapy pathway: randomised trial in 200 women with breast cancer Klinkhammer-Schalke, M Koller, M Steinger, B Ehret, C Ernst, B Wyatt, J C Hofstädter, F Lorenz, W Br J Cancer Clinical Study BACKGROUND: Despite thousands of papers, the value of quality of life (QoL) in curing disease remains uncertain. Until now, we lacked tools for the diagnosis and specific treatment of diseased QoL. We approached this problem stepwise by theory building, modelling, an exploratory trial and now a definitive randomised controlled trial (RCT) in breast cancer, whose results we report here. METHODS: In all, 200 representative Bavarian primary breast cancer patients were recruited by five hospitals and treated by 146 care professionals. Patients were randomised to either (1) a novel care pathway including diagnosis of ‘diseased’ QoL (any QoL measure below 50 points) using a QoL profile and expert report sent to the patient's coordinating practitioner, who arranged QoL therapy consisting of up to five standardised treatments for specific QoL defects or (2) standard postoperative care adhering to the German national guideline for breast cancer. The primary end point was the proportion of patients in each group with diseased QoL 6 months after surgery. Patients were blinded to their allocated group. RESULTS: At 0 and 3 months after surgery, diseased QoL was diagnosed in 70% of patients. The QoL pathway reduced rates of diseased QoL to 56% at 6 months, especially in emotion and coping, compared with 71% in controls (P=0.048). Relative risk reduction was 21% (95% confidence interval (CI): 0–37), absolute risk reduction 15% (95% CI: 0.3–29), number needed to treat (NNT)=7 (95% CI: 3–37). When QoL therapy finished after successful treatment, diseased QoL often returned again, indicating good responsiveness of the QoL pathway. CONCLUSION: A three-component outcome system including clinician-derived objective, patient-reported subjective end points and qualitative analysis of clinical relevance was developed in the last 10 years for cancer as a complex intervention. A separate QoL pathway was implemented for the diagnosis and treatment of diseased QoL and its effectiveness tested in a community-based, pragmatic, definitive RCT. While the pathway was active, it was effective with an NNT of 7. Nature Publishing Group 2012-02-28 2012-02-07 /pmc/articles/PMC3305975/ /pubmed/22315052 http://dx.doi.org/10.1038/bjc.2012.4 Text en Copyright © 2012 Cancer Research UK https://creativecommons.org/licenses/by-nc-sa/3.0/This work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
spellingShingle Clinical Study
Klinkhammer-Schalke, M
Koller, M
Steinger, B
Ehret, C
Ernst, B
Wyatt, J C
Hofstädter, F
Lorenz, W
Direct improvement of quality of life using a tailored quality of life diagnosis and therapy pathway: randomised trial in 200 women with breast cancer
title Direct improvement of quality of life using a tailored quality of life diagnosis and therapy pathway: randomised trial in 200 women with breast cancer
title_full Direct improvement of quality of life using a tailored quality of life diagnosis and therapy pathway: randomised trial in 200 women with breast cancer
title_fullStr Direct improvement of quality of life using a tailored quality of life diagnosis and therapy pathway: randomised trial in 200 women with breast cancer
title_full_unstemmed Direct improvement of quality of life using a tailored quality of life diagnosis and therapy pathway: randomised trial in 200 women with breast cancer
title_short Direct improvement of quality of life using a tailored quality of life diagnosis and therapy pathway: randomised trial in 200 women with breast cancer
title_sort direct improvement of quality of life using a tailored quality of life diagnosis and therapy pathway: randomised trial in 200 women with breast cancer
topic Clinical Study
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3305975/
https://www.ncbi.nlm.nih.gov/pubmed/22315052
http://dx.doi.org/10.1038/bjc.2012.4
work_keys_str_mv AT klinkhammerschalkem directimprovementofqualityoflifeusingatailoredqualityoflifediagnosisandtherapypathwayrandomisedtrialin200womenwithbreastcancer
AT kollerm directimprovementofqualityoflifeusingatailoredqualityoflifediagnosisandtherapypathwayrandomisedtrialin200womenwithbreastcancer
AT steingerb directimprovementofqualityoflifeusingatailoredqualityoflifediagnosisandtherapypathwayrandomisedtrialin200womenwithbreastcancer
AT ehretc directimprovementofqualityoflifeusingatailoredqualityoflifediagnosisandtherapypathwayrandomisedtrialin200womenwithbreastcancer
AT ernstb directimprovementofqualityoflifeusingatailoredqualityoflifediagnosisandtherapypathwayrandomisedtrialin200womenwithbreastcancer
AT wyattjc directimprovementofqualityoflifeusingatailoredqualityoflifediagnosisandtherapypathwayrandomisedtrialin200womenwithbreastcancer
AT hofstadterf directimprovementofqualityoflifeusingatailoredqualityoflifediagnosisandtherapypathwayrandomisedtrialin200womenwithbreastcancer
AT lorenzw directimprovementofqualityoflifeusingatailoredqualityoflifediagnosisandtherapypathwayrandomisedtrialin200womenwithbreastcancer